GlassScriptPhysician profile
Eric K Chin
NPI 1043442809
$11,463.09
in general payments reported to CMS, 2019-2025
27 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $190 · 2021: $2,360 · 2022: $3,097 · 2023: $1,243 · 2024: $2,537 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971 · Consulting Fee: $1,550 · Education: $97.99 · Honoraria: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.48 |
| Consulting Fee | $1,550.00 |
| Education | $97.99 |
| Honoraria | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,497.07 | 2021-2024 | Iluvien, Yutiq |
| Allergan, INC. | $2,046.08 | 2019-2021 | |
| Abbvie INC. | $2,022.35 | 2022-2025 | Ozurdex |
| Genentech USA, INC. | $668.37 | 2019-2025 | Vabysmo |
| Genentech, INC. | $655.85 | 2019-2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $523.82 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $511.12 | 2020-2025 | Acthar |
| Vertex Pharmaceuticals Incorporated | $350.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $330.47 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $320.55 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $191.74 | 2023-2025 | Izervay |
| Sandoz INC. | $183.53 | 2024-2025 | Cimerli |
| Dutch Ophthalmic, USA | $171.51 | 2023 | Tissueblue, Eva, Combined Machine |
| Amgen INC. | $165.11 | 2025 | Tepezza |
| Coherus Oncology, INC. | $135.19 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Horizon Therapeutics Plc | $108.58 | 2022-2023 | Tepezza |
| Optos, INC. | $86.67 | 2019 | |
| Biogen, INC. | $84.27 | 2023-2024 | Byooviz |
| Ani Pharmaceuticals, INC. | $80.03 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $64.60 | 2023-2025 | Miebo, Xipere, Xiidra |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $20.00 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $17.72 | 2021 | |
| Alcon Vision LLC | $14.97 | 2022 | |
| Vyera Pharmaceuticals, LLC | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.